

III. REMARKS AND CONCLUSION

Claims 12-16 are pending. No substantive amendments are made to the Claims. Accordingly, no estoppel should result. Only typographical amendments have been made.

A. Priority

The Claims filed in the instant application are not disclosed but unclaimed subject matter of the parent case. Rather, the Claims are embodiments of the allowed Claims of US Pat. No. 6,670,340.

B. Claim Objections

All claim objections have been cured.

C. Rejections under 35 USC §1.12, 2nd ¶


Applicants have corrected the dependency issues. These were merely typographical in nature.

D. Double Patenting

Applicant has included a terminal disclaimer, the fee for which should be charged to deposit account 02-2334. This is expected to Clear the rejections of 12-16 over US Patent 6,670,340.

The application is believed in a condition for allowance and Applicant respectfully requests such action. If the Examiner feels that an interview may best further the prosecution of the case, Applicant extends an invitation for the Examiner to call the below undersigned attorney for any assistance in securing allowance of this application. Please charge deposit account number 02-2334 for any required fees.

Sincerely,



William P. Ramey, III
Reg. No. 44,295

Akzo Nobel Pharma Patent Department
29160 Intervet Lane
Millsboro, DE 19966
(302) 933-4034 telephone
(302) 933-4305 facsimile

USSFN: 10/603,355

6